British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

With the uncertainty caused by recent Zantac litigation now over ... Lagonda shares have improved 5.3p to 110.8p after the car maker reassured investors it is on track to meet September’s ...

On Tuesday, U.S. District Judge Brian Cogan in New York dismissed key consumer claims in the multidistrict litigation against ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

Sales of GSK's key vaccine Arexvy slumped 72% at constant currency to 188 million pounds after U.S. health officials in June restricted the shot to a smaller age range and more at-risk patients.

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously filed by Valisure. The arrangement is awaiting final approval from the Department of Justice.

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.